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The Role of Riboflavin Concentration and
Oxygen in the Efficacy and Depth of Corneal
Crosslinking
The recent article of O’Brart et al.1 discussed the roles of
riboflavin concentration (in the stroma) on the efficacy of
corneal collagen crosslinking (CXL). Clinical studies of Ng et
al.2 showed that accelerated CXL (ACXL) had less efficacy than
standard CXL (SCXL) for the same fluence (dose) based on
Bunsen–Roscoe reciprocal law (BRL). To overcome this
intrinsic drawback of ACXL, Lin3 recently proposed a new
protocol called riboflavin (Rf) concentration-controlled method
(CCM) to improve the efficacy of ACXL by supplemental Rf
during the UV exposure to compensate the fast depletion of Rf
by UV light.
This letter analyzes the role of Rf concentration and its
limitation by a CXL depth formula. A new criterion of CXL
efficacy based on crosslinking [strength] · [depth] is intro-
duced for optimal protocol. In addition, the role of oxygen in
both type-I and type-II CXL is briefly summarized.
CXL efficacy4,5 defined by Eff ¼ 1 - exp(-S), where the S-
function for type-I and type-II CXL is shown in the Table. Our
numerical calculations5 showed that S2 follows BRL and is
proportional to the light dose (E0) and C[O2]. In contrast, non-
BRL feature occurs in type-I CXL (or S1) to be analyzed late. In
contrast to the conventional belief that oxygen-mediated type-II
plays the critical role of CXL, the kinetic model of Kamaev et
al.6 showed that CXL is predominated by type-I, whereas
oxygen (or type-II) plays only a limited and transient role. Lin’s
3-pathway model5,7 showed mathematical details of the role of
oxygen, supporting the claim of Kamaev et al.6 Moreover, a
recent clinical study of Lombardo et al.8 showed a simple-
exponential temporal profile of Rf concentration that implied
that, in ambient environment, non–oxygen-mediated type-I
mechanism is predominant.
For type-I CXL, the S-function (S1) is shown in the Table,
where F(z)C0 is the initial (at t ¼ 0) Rf concentration (in the
stroma) having a depth-profile defined by a diffusion depth (D),
F(z) ¼ 1–0.5z/D. In contrast to type-II (S2), in which oxygen
plays a transient but critical role, type-I (S1) does not require
oxygen and it is the predominant pathway of CXL efficacy.4–8
At steady-state (with btX>>1), S1 follows a nonlinear
scaling law4 that S1 is proportional to (FC0/I0)
0.5 exp(0.5Az),
or S1a[C0]0.5 (for z ¼ 0) and stronger dependence of
S1a[C0exp(Az)]0.5 (for z > 0), because A is also proportional
to C0. For example, on corneal surface (or z ¼ 0), when C0 is
doubled (from 0.1% to 0.2%), S1 increases by a factor of 1.43.
The Figure shows the theoretical Rf dose-curve (or S1 versus
C0) comparing to the data of O’Brart et al.
1 (their Fig. 3A,
normalized, and fit at 0.1%); both show the nonlinear feature of
S1aC00.5.
CXL depth (defined by when S1 is maximal) is given by7 z*¼
ln(NE0)/A, with N being a numerically fit constant given by N¼
0.16 (for D >>1 cm) and N ¼ 0.224 (for D ¼ 500 lm). For
example, when C0 is doubled (from 0.1% to 0.2%), A increases
and z* is reduced by 1.48 times. The z*-formula shows that
higher Rf concentration results in an increased (or larger S1),
but more superficial (or small z*) crosslinking effect, as also
indicated by O’Brart et al.1 Our formulas lead to a new criterion
of CXL efficacy based on the product of CXL [strength] (or S1)
and [depth] (or z*), that is, the [volume] of stroma being cross-
linked. For a given C0, deeper CXL may be achieved by larger
fluence (E0). However, to achieve clinically acceptable CXL
efficacy by a minimal E0, one requires an optimal range of C0.
For example, C0 ¼ 0.15% to 0.3%, and E0 ¼ 3.5 to 4.5 J/cm2,
such that [depth], z* ¼ 200 to 300 lm, and [strength], S1 ¼ 1.5
to 2.0, or CXL efficacy Eff ¼ 1 - exp(-S1) ¼ 0.78 to 0.86. Our
formulas also demonstrate that epi-on CXL (having a smaller D
and C0) is less efficient than epi-off CXL, as clinically reported.
To conclude, the author would like to see further basic, clinical
investigations to support the presented formulas, as suggested
by the reviewers.
Jui-teng Lin
New Vision, Inc., Taipei, Taiwan
E-mail: jtlin55@gmail.com
TABLE. Abbreviations and Key Parameters4,5
CXL Corneal Collagen Crosslinking
SCXL Standard CXL (intensity 3 mW/cm2)
ACXL Accelerated CXL (intensity 9 to 45 mW/cm2)
BRL Bunsen–Roscoe reciprocal law
CCM Riboflavin (Rf) concentration-controlled method
CXL efficacy
S-functions
S1 ¼ K ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃF zð ÞCo= bXð Þp 1  exp 0:5btXð Þ½ 
S2 ¼ R t0 bC O2½ = O2½  þ kð Þdt
X = exp (-Az); b ¼ 0:62pkI0
C0 Initial Rf concentration (at z ¼ 0)
[O2] Concentration of oxygen
F(z) Depth-profile of Rf, with a diffusion depth (D)
E0 ¼ tI0 UV light fluence (dose)
I0 UV light intensity
t Exposure time
p Quantum yield of Rf triplet state
KI A rate constant
A
m
Effective absorption, A ¼ 290 m(1 – 0.25 z/D)C0 þ 32
Fit parameter ¼ 0.4 to 0.6.
FIGURE. CXL efficacy versus Rf concentration shows the nonlinear
feature, where theoretical curve (red curve) is compared with the
clinical data (bars) of O’Brart et al.1
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